$1.77
Revenue is down for the last 3 quarters, 51.57M → 342.0K (in $), with an average decrease of 91.8% per quarter
Netprofit is down for the last 2 quarters, -74.57M → -74.77M (in $), with an average decrease of 0.3% per quarter
In the last 1 year, Seagen Inc has given 36.8% return, outperforming this stock by 102.8%
In the last 3 years, Moderna Inc has given 23.1% return, outperforming this stock by 107.7%
0.65%
Downside
Day's Volatility :5.96%
Upside
5.35%
1.13%
Downside
52 Weeks Volatility :81.26%
Upside
81.05%
Period | Atara Biotherapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -56.3% | 0.3% | -6.7% |
6 Months | -60.93% | -8.3% | -6.2% |
1 Year | -65.96% | -4.8% | -6.3% |
3 Years | -83.94% | 23.8% | 26.9% |
Market Capitalization | 173.4M |
Book Value | $0.67 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.93 |
PEG Ratio | 0.0 |
Wall Street Target Price | 16.13 |
Profit Margin | 0.0% |
Operating Margin TTM | -454.56% |
Return On Assets TTM | -46.7% |
Return On Equity TTM | -148.63% |
Revenue TTM | 57.5M |
Revenue Per Share TTM | 0.56 |
Quarterly Revenue Growth YOY | -83.2% |
Gross Profit TTM | 63.6M |
EBITDA | -256.0M |
Diluted Eps TTM | -1.93 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.64 |
EPS Estimate Next Year | -1.9 |
EPS Estimate Current Quarter | -0.39 |
EPS Estimate Next Quarter | -0.63 |
What analysts predicted
Upside of 811.3%
Sell
Neutral
Buy
Atara Biotherapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Atara Biotherapeutics Inc | -37.01% | -60.93% | -65.96% | -83.94% | -96.42% |
![]() Moderna, Inc. | -5.37% | -28.24% | -13.14% | 103.02% | 578.71% |
![]() Regeneron Pharmaceuticals, Inc. | -10.12% | -3.55% | 9.07% | 20.95% | 140.97% |
![]() Seagen, Inc. | -2.85% | 59.4% | 42.61% | 21.68% | 240.77% |
![]() Vertex Pharmaceuticals Incorporated | -4.35% | 4.3% | 22.83% | 15.12% | 110.67% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Atara Biotherapeutics Inc | NA | NA | 0.0 | -2.64 | -1.49 | -0.47 | 0.0 | 0.67 |
![]() Moderna, Inc. | 11.22 | 11.22 | 0.0 | -1.83 | 0.27 | 0.12 | 0.0 | 49.12 |
![]() Regeneron Pharmaceuticals, Inc. | 19.72 | 19.72 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
![]() Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
![]() Vertex Pharmaceuticals Incorporated | 26.53 | 26.53 | 0.41 | 13.64 | 0.26 | 0.17 | 0.0 | 56.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Atara Biotherapeutics Inc | Buy | $173.4M | -96.42% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $48.1B | 578.71% | 11.22 | 31.77% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $79.5B | 140.97% | 19.72 | 33.81% |
![]() Seagen, Inc. | Hold | $36.3B | 240.77% | NA | -31.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $85.0B | 110.67% | 26.53 | 35.4% |
BlackRock Inc
Baupost Group LLC
Wasatch Advisors Inc.
State Street Corporation
JPMorgan Chase & Co
Vanguard Group Inc
Atara Biotherapeutics Inc’s price-to-earnings ratio stands at None
Read MoreAtara Biotherapeutics, Inc.(@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With its lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Its platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel® in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients' lives is its mission and it will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and its leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.
Organization | Atara Biotherapeutics Inc |
Employees | 330 |
CEO | Dr. Pascal Touchon D.V.M. |
Industry | Health Technology |
First Majestic Silver Corp
$5.75
-0.17%
ONYX ACQUISITION CO. I
$11.00
+3.29%
Diversified Healthcare Trust
$1.14
-0.87%
ALTC ACQUISITION CORP-CL A
$10.65
+0.19%
iShares Morningstar Value ETF
$63.41
+0.94%
Nationwide Nasdaq-100 Risk-Managed Income ETF
$20.48
+0.29%
ENFUSION INC
$7.88
+1.03%
WisdomTree Trust - WisdomTree International Quality Dividend Growth Fund
$33.86
+1.2%
GIGACLOUD TECHNOLOGY INC
$6.45
+11.4%